Trial Profile
A Phase I Trial of the Farnesyltransferase Inhibitor, R115777 (NSC# 702818) and Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 31 Mar 2023
Price :
$35
*
At a glance
- Drugs Tipifarnib (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions
- 13 Apr 2020 Status changed from active, no longer recruiting to completed.
- 26 Oct 2009 New trial record